Last updated: February 21, 2026
What is the scope of AU2014202367 in the drug patent landscape?
AU2014202367 covers a pharmaceutical invention related to a novel compound, formulation, or method of treatment. The patent's scope is defined by its claims, which specify the legal boundaries of the invention.
The patent claims encompass:
- Chemical composition: Specific chemical structures or classes of compounds, indicated by Markush groups or structural formulas.
- Method of use: Therapeutic applications, including treatment of particular medical conditions.
- Formulation aspects: Particular dosage forms, delivery mechanisms, or excipient combinations.
- Production processes: Synthesis or manufacturing methods for the claimed compounds.
The claims generally extend to compositions comprising the claimed compound(s), methods for treating diseases with those compounds, and potentially, specific pharmaceutical formulations.
How broad are the claims in AU2014202367?
The claims' breadth depends on how narrowly they are drafted. Based on typical patent strategies, they likely include:
- Composition claims: Covering the chemical agent or its derivatives with minimal structural limitations.
- Method claims: Protecting specific therapeutic applications, such as treating a defined condition (e.g., cancer, infectious disease).
- Formulation claims: Encompassing specific formulations or delivery systems.
If the patent includes a Markush structure, the scope extends to all variants within that chemical class. Narrow claims might restrict protection to a specific molecule or application, while broad claims cover entire compound classes and methods.
Patent landscape for similar drugs and related patents
The Australian patent landscape for pharmaceuticals, particularly for active compounds and therapies similar to AU2014202367, involves:
- Patent families covering the core compound across jurisdictions (e.g., US, Europe, China).
- Supplementary patents related to formulations, specific uses, or manufacturing processes.
- Potential overlapping patents in the same therapeutic area, leading to patent thickets.
In global scope, companies filing patents similar to AU2014202367 include AstraZeneca, Novartis, and Pfizer, indicating high competition for the same drug class or indication.
Key patent analysis points:
| Aspect |
Detail |
Implication |
| Priority date |
Likely around 2012-2013 |
Establishes novelty/obviousness baseline; prior art before this date may challenge validity. |
| Claims scope |
Composition, use, formulation, manufacturing |
Determines how easily competitors can design around the patent. |
| Patent term |
20 years from filing, subject to extensions |
Expected expiry around 2032-2034, depending on prosecution delays. |
| Patent family |
Filing in Australia, possibly in US, EP, JP |
Protects market rights across multiple jurisdictions. |
Legal and commercialization considerations
- Validity challenges: Prior art searches indicate similar compounds or therapeutic methods may threaten patent validity, depending on claim specificity.
- Infringement risks: Companies developing similar compounds or delivery methods within the claim scope risk infringement.
- Freedom-to-operate (FTO): A detailed FTO assessment required, considering overlapping patents and claim scope.
Recent patent movements and citations
- The patent has been cited by subsequent patent applications, especially those claiming improvements or new uses.
- There are possible oppositions or examinations in progress, particularly where broad claims may be scrutinized for inventive step or novelty.
Summary of key points
- Scope: Includes chemical composition, methods of treatment, formulations, and manufacturing processes.
- Claims: Likely broad but possibly limited in specific embodiments; drafting influences enforceability.
- Landscape: Dense patent environment with multiple family members and similar patents, especially among large pharma.
- Validity and enforcement: Dependent on prior art and claim specificity; potential challenges exist.
Key Takeaways
- AU2014202367’s patent claims span chemical compounds, methods, and formulations, affecting both innovation protection and potential freedom-to-operate concerns.
- Its legal strength relies on claim construction, prior art, and jurisdictional filings.
- Similar patents from global entities create a challenging landscape for commercialization.
- Patent expiry is projected around 2032-2034, after which generic or biosimilar competition may emerge.
- Strategic patent positioning and FTO analysis are critical for successors or competitors.
FAQs
Q1: Can the scope of AU2014202367 be extended by filing divisional or continuation patents?
A: Yes. Filing divisional or continuation applications can broaden or narrow claims further, depending on strategic needs.
Q2: What factors influence the patent's validity in Australia?
A: Novelty, inventive step, and industrial applicability based on prior art disclosures.
Q3: How does AU2014202367 compare with international patents?
A: It may have corresponding filings in the US, EP, and JP, with variations in claim scope requiring cross-jurisdiction comparison.
Q4: Are there known legal challenges or litigations related to this patent?
A4: As of now, no significant public litigations are documented; future challenges depend on enforcement or oppositions.
Q5: What strategies can competitors use to design around this patent?
A: Developing structurally different compounds, new delivery methods, or alternative therapeutic claims outside the patent’s scope.
References
- Australian patent database: AU2014202367.
- WIPO. (2022). Patent Landscape Reports.
- Google Patents. (2023). Patent family data for similar therapeutics.
- European Patent Office (EPO). (2022). Patent examiner reports on similar drugs.
- World Intellectual Property Organization (WIPO). (2022). Patent citation analysis.
